Welcome to our dedicated page for Medicenna Therapeutics news (Ticker: MDNAF), a resource for investors and traders seeking the latest updates and insights on Medicenna Therapeutics stock.
Medicenna Therapeutics reports developments as a clinical-stage immunotherapy company developing proprietary Superkines for cancer, autoimmune and inflammatory diseases. Recurring updates center on MDNA11, a long-acting IL-2 Superkine; MDNA113, a tumor-targeted and conditionally activated anti-PD-1 x IL-2 bifunctional Superkine; and bizaxofusp, formerly MDNA55, an IL-4 Empowered Superkine studied in glioblastoma.
Company news also includes clinical and preclinical data presentations at oncology and healthcare conferences, corporate and financial updates, collaborations around investigator-initiated trials, and governance changes such as board and medical leadership appointments.
Medicenna Therapeutics Corp. (NASDAQ: MDNA TSX: MDNA) announced that Dr. Fahar Merchant, CEO, will present at multiple investor conferences in March 2021. These include the H.C. Wainwright Global Life Sciences Conference, with a pre-recorded presentation available on-demand from March 9, and the Oppenheimer 31st Annual Healthcare Conference, featuring a live presentation on March 17. Additionally, Dr. Merchant will participate in a live panel discussion at the Maxim 2021 Emerging Growth Virtual Conference on the same day. Details for accessing the webcasts are available on Medicenna's Investor Relations website.
Medicenna Therapeutics Corp. (NASDAQ: MDNA; TSX: MDNA) announced that CEO Dr. Fahar Merchant will present a corporate overview at the 41st Annual Cowen Healthcare Conference on March 2, 2021, at 2:10 PM ET. Interested parties can access a live webcast here. The presentation replay will be available on Medicenna's Investor Relations page. The company focuses on immunotherapy with assets like MDNA11 and MDNA55, targeting various cancers and has obtained Fast-Track designation from the FDA.
Medicenna Therapeutics Corp. (NASDAQ: MDNA TSX: MDNA) announced that Dr. Fahar Merchant will present at the 10th Annual Leerink Global Healthcare Conference on February 26, 2021, at 3:00 PM ET. Investors can access a live webcast on Medicenna's Investor Relations website. Medicenna focuses on developing novel immunotherapies, including MDNA11, a long-acting IL2 Superkine, and MDNA55, which has completed a Phase 2b trial for rGBM, a deadly brain cancer. MDNA55 has received Fast-Track and Orphan Drug designation from the FDA.
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) reported financial results for the quarter ended December 31, 2020, showing a net loss of $5.3 million, or $0.11 per share, compared to a loss of $2.4 million, or $0.07 per share in the same quarter of 2019. Key highlights include FDA acceptance of the hybrid trial design for MDNA55 in recurrent glioblastoma and positive feedback from the UK’s MHRA for the MDNA11 Phase 1/2 trial. The company had cash and equivalents of $33.2 million, with additional funds received post-quarter amounting to approximately $7.8 million.
Medicenna Therapeutics announced the presentation of two abstracts at the EORTC-NCI-AACR Virtual Scientific Program, scheduled for October 24-25, 2020. The first abstract discusses long-term survival results from the MDNA55-05 trial in recurrent glioblastoma multiforme, presented by Dr. John Sampson. The second abstract features updated pre-clinical data on MDNA11 and novel bi-specific IL-13 superkines, presented by Dr. Minh To. Both presentations will be available for on-demand viewing at Medicenna’s website after the event.
Medicenna Therapeutics (NASDAQ: MDNA) has received FDA approval for a hybrid registration trial design for its MDNA55 treatment targeting recurrent glioblastoma (rGBM). This innovative approach will use matched external controls for two-thirds of the control arm, reducing participant enrollment and trial costs while expediting regulatory approval. The design aims to generate robust overall survival data, potentially setting a new precedent for oncology trials. With previous promising results, the company looks to advance its partnership strategy for future development.